World's Best Scientists 2026 revealed!
Ramesh K. Ramanathan

Ramesh K. Ramanathan

D-Index & Metrics

Medicine

D-Index
86
Citations
42064
World Ranking
13874
National Ranking
7042

Overview

Ramesh K. Ramanathan is affiliated with the Mayo Clinic in the United States and has contributed extensively to the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their research spans several specialized areas, including Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Biomaterials.

Their work primarily focuses on key topics such as:

  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Nanoparticle-Based Drug Delivery
  • Cancer Treatment and Pharmacology
  • Gastric Cancer Management and Outcomes
  • PI3K/AKT/mTOR signaling in cancer
  • Lung Cancer Treatments and Mutations

Ramanathan has published research in several notable venues, including:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Targeted Oncology
  • Molecular Cancer Therapeutics
  • British Journal of Clinical Pharmacology

Their recent publications demonstrate a focus on clinical trials and targeted therapies in cancer treatment. Some significant papers include:

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, 2023, Journal of Clinical Oncology
  • Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours, 2020, British Journal of Clinical Pharmacology
  • Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer, 2020, Targeted Oncology
  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors, 2020, Molecular Cancer Therapeutics
  • Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors, 2021, Molecular Cancer Therapeutics

Ramanathan frequently collaborates with other researchers, including:

  • Daniel D. Von Hoff
  • Richard M. Goldberg
  • Daniel J. Sargent
  • Roscoe F. Morton
  • Charles S. Fuchs

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

    Richard M. Goldberg;Daniel J. Sargent;Roscoe F. Morton;Charles S. Fuchs

  • Outcomes After Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity

    Philip R. Schauer;Sayeed Ikramuddin;William Gourash;Ramesh Ramanathan

  • Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus.

    Philip R Schauer;Bartolome Burguera;Sayeed Ikramuddin;Dan Cottam

  • Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    J. Philip Kuebler;H. Samuel Wieand;Michael J. O'Connell;Roy E. Smith

  • Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru

  • Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

    Howard S. Hochster;Lowell L. Hart;Ramesh K. Ramanathan;Barrett H. Childs

  • Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

    Mace L. Rothenberg;Amit M. Oza;Robert H. Bigelow;Jordan D. Berlin

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

    William D Tap;Zev A Wainberg;Stephen P Anthony;Prabha N Ibrahim

  • Surgically-Induced Weight Loss Significantly Improves Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome

    Samer G. Mattar;Laura M. Velcu;Mordechai Rabinovitz;A J. Demetris

  • Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis

    Bodour Salhia;Jeff Kiefer;Julianna T. D. Ross;Raghu Metapally

  • Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

    Hanna K. Sanoff;Daniel J. Sargent;Megan E. Campbell;Roscoe F. Morton

  • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

    Helmut Oettle;D. Richards;R. K. Ramanathan;J. L. van Laethem

  • Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

    Johann de Bono;Ramesh K. Ramanathan;Lida Mina;Rashmi Chugh

  • Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

    Rachna T. Shroff;Milind M. Javle;Lianchun Xiao;Ahmed O. Kaseb

  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Davendra P.S. Sohal;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramesh K. Ramanathan;Chandra P. Belani;Deepti A. Singh;Michael Tanaka

Frequent Co-Authors

Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Chandra P. Belani
Chandra P. Belani Penn State Cancer Institute
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
David Goldstein
David Goldstein University of New South Wales
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Patricia LoRusso
Patricia LoRusso Yale University
Howard S. Hochster
Howard S. Hochster Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career in the USA, there are many alternative online degrees and career pathways that can complement or provide entry into the healthcare field. One popular route is through medical billing and coding schools that accept financial aid, which allow individuals to begin working in healthcare administration without incurring high upfront costs.

For those interested in direct patient care but wanting to streamline the admissions process, consider nursing schools that don't require teas or hesi. These programs can make it easier and faster to start your nursing education by removing standardized testing barriers.

Additionally, growing demand for healthcare leaders has increased interest in healthcare administration degrees, which can often be completed online at an accelerated pace. For registered nurses aiming to advance their careers, adn to np bridge programs offer a direct path to becoming a nurse practitioner.

These flexible educational options can help you gain valuable skills, meet evolving healthcare demands, and progress within various medical career pathways in the United States.

Best Scientists Citing Ramesh K. Ramanathan

Trending Scientists